A-Alpha Bio

The design work is done by a model. AlphaBind is trained on the company's interaction data to predict binding from sequence and to propose antibodies, and that prediction and design is the capability a partner comes for. It sits on top of AlphaSeq, the measurement platform, which is real value in its own right and the source of the data, so the company is not only its models. But the thing that turns measurements into a designed antibody is the learned model, and that half of the business does not exist without it.

A-Alpha runs a loop a partner can follow: the model proposes a design, AlphaSeq measures it, and the measurement feeds back to validate and refine. What the loop does not come with is a stated control, when a prediction is trusted or set aside, what a contradicting measurement does to a program, and which calls a person makes. The experiment is the oversight, which works in practice but is not written down as a rule.

The model is named and its approach is clear. AlphaBind is a set of models trained on the company's own protein interaction data to predict binding from sequence, and the relationship to AlphaSeq, which generates that training data, is described. What is not published is the layer beneath: no architecture, parameter count or training data size is given, and no version or update practice ties a design to a dated model.

The models and the measurement platform are the company's own, and no outside model provider is named as sitting between data and a design. Beyond that nothing is established: no compute or hosting provider is named, no third party components are listed, there is no subprocessor list, and nothing describes what governs a partner's data once it enters the system.

The evidence is a roster of serious partners and a large measured dataset, with no clinical result yet. A-Alpha names collaborators including Bristol Myers Squibb, Amgen, Gilead and the Gates Foundation, work funded by the United States Department of Defense on antibodies against biological threats, and more than a billion protein interactions measured on AlphaSeq.

What is missing is a program from the platform named in a clinical trial and a peer reviewed evaluation of how well AlphaBind designs, so the checkable signal is who works with the company and how much data it holds, not an outcome in a patient.

The inputs are protein and interaction data rather than patient records, so no protected health information is involved. What a collaborator would want settled is the fate of its own data on a platform whose value is a shared pool of measurements: whether that data is retained, used in training, or kept apart from other work. A-Alpha does not describe how any of that is handled.

A-Alpha works with protein interaction data rather than patient records, so United States health privacy rules do not touch what it handles. No business associate position and no platform level privacy document are published, which a pharmaceutical partner's data review would note even though no patient data is in play.

Large pharmaceutical partners hand A-Alpha their data, the kind of relationship where a security team expects an attestation it can open: a SOC 2 report, an ISO 27001 or HITRUST certification, or at least a trust portal. The company names none of these and runs no security page, so there is no outside account of how that data is protected.

No device claim is made, and the platform is scoped to match. A-Alpha works at the discovery stage, measuring interactions and designing antibodies, so any regulatory position belongs to the molecules and the partners that develop them. There is no clearance to hold and none is claimed.

The company's account of its model is a method, that measured data from AlphaSeq validates and refines the models. A buyer judging governance needs the next thing, an evaluation of how reliably those models predict and where they fail, a benchmark, an audit, or a responsible AI policy. The method of refining on measured data is not that evaluation, and none of those governance artifacts appears.

When an AlphaBind prediction does not pan out, a partner wants a sense of how often that happens and what recourse exists. No success or error rate with a method and a denominator is published, so there is no figure to plan against, and no guarantee, indemnity or correction route travels with a design. That risk is settled inside the private collaboration agreements.

The platform is a measurement method paired with a set of models, not software a buyer wires into a stack, so there is no clinical record surface involved, as a discovery platform would not have one. The research side is just as self contained: no electronic lab notebook, laboratory information management system or research data platform is named as connected, and no connector is offered.

The platform runs for A-Alpha and its partners rather than being deployed to anyone, so there is no tenancy or hosting model to evaluate. Location is implied by the company's base in Seattle rather than committed, and nothing published names where partner data rests or how one collaboration's data is kept apart from another's on the shared data platform.

A-Alpha earns through partnerships and funded programs rather than selling access, so no price is posted. The public figures, a $22.4 million Series A2 and a $14.5 million Department of Defense award, are money raised rather than a price a buyer could pay, so the way the company funds itself is visible while the cost of engaging it is not.

Coverage is named by interaction type, with the measured data behind part of it. A-Alpha works on antibody and antigen pairs, on degrader targets described as E3 ligase and neo-substrate interactions, and on engineering protein interfaces generally, and reports having measured those interaction types at scale.

What is not established is therapeutic reach: no disease area, indication or clinical program is named, so the coverage is described in terms of the biology it measures rather than the conditions a drug would treat.